ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Protalix BioTherapeutics, Chiesi Global Announce BLA Acceptance of Pegunigalsidase Alfa
August 14, 2020Protalix BioTherapeutics together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted ...
Pharma Sources Insight January 2025
